The global transcatheter mitral valve market is on a strong growth trajectory, with projections estimating a market valuation of USD 1.6 billion by the end of 2024 and an impressive compound annual ...

By group, procedural success and freedom from LVOT obstruction (LVOT mean gradient > 50 mm Hg), the primary efficacy endpoint ...

MemorialCare offers advanced, minimally invasive heart treatments like TAVR & MitraClip as alternatives to open-heart surgery ...

Accordingly, we prefer valve replacement as the treatment of choice for severe mitral regurgitation secondary to ruptured chordae tendineae. Thirty-nine cases of severe mitral regurgitation ...

However, they may need to be replaced again in the future. Read more about heart valve replacement surgery. TAVI is an alternative treatment for aortic stenosis, which is increasingly offered instead ...

Nitinol is commonly used in replacement heart valve frames, but that’s not how the new Edwards Lifesciences Sapien M3 transcatheter mitral valve replacement ... providing an important new treatment ...

Aortic stenosis is a serious heart valve condition characterized by narrowing ... support to those unable to afford this life-saving treatment. This initiative ensures that cutting-edge therapies ...

After acquiring its developer last year, Edwards Lifesciences has now obtained a European approval for what it described as the world’s first transfemoral transcatheter mitral valve replacement ...

The company received CE marks for its Pascal mitral and tricuspid valve repair devices in 2019 and 2020 ... year label expansion supported by data in asymptomatic severe aortic stenosis patients.

today announced the company’s SAPIEN M3 mitral valve replacement system received CE Mark for the transcatheter treatment of patients with symptomatic (moderate-to-severe or severe) mitral ...